Cochrane · systematic review · CD011440
Exhaled nitric oxide levels to guide treatment for adults with asthma
Petsky, HL, Kew, KM, Turner, C, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 33.3%Low 0 · 0%Moderate 2 · 66.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Tailoring asthma treatment using FeNO versus clinical symptoms
Population: adults with asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants who had ≥ 1 exacerbations over study period Tailoring asthma treatment using FeNO vs clinical symptoms | OR 0.6 [0.43, 0.84] | 5 studies · 1005 participants | Moderate Downgraded: risk of bias |
Number of exacerbations per 52 weeks (exacerbation rates) Tailoring asthma treatment using FeNO vs clinical symptoms | no estimate extracted | 5 studies · 842 participants | Moderate Downgraded: risk of bias |
ICS dose at final visit Tailoring asthma treatment using FeNO vs clinical symptoms | no estimate extracted | 4 studies · 582 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |